![basal insulin and glp-1 Adding a receptor agonist was not associated with a lower likelihood of discontinuing existing therapy among veterans with type 2 diabetes compared with other glucose-lowering agents, a target emulation glp-1_analogs [TUSOM | Pharmwiki]](https://lookaside.instagram.com/seo/google_widget/crawler/?media_id=3941402989327981257)
basal insulin and glp-1
Shipping Estimate
basal insulin and glp-1 Adding a receptor agonist was not associated with a lower likelihood of discontinuing existing therapy among veterans with type 2 diabetes compared with other glucose-lowering agents, a target emulation glp-1_analogs [TUSOM | Pharmwiki]
EUR24.81
EUR60.81
Pay in 4 interest-free payments of $6.20 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
![basal insulin and glp-1 Adding a receptor agonist was not associated with a lower likelihood of discontinuing existing therapy among veterans with type 2 diabetes compared with other glucose-lowering agents, a target emulation glp-1_analogs [TUSOM | Pharmwiki]](https://tmedweb.tulane.edu/pharmwiki/lib/exe/fetch.php/glp1.png?w=600&tok=baf39c)
![basal insulin and glp-1 Adding a receptor agonist was not associated with a lower likelihood of discontinuing existing therapy among veterans with type 2 diabetes compared with other glucose-lowering agents, a target emulation glp-1_analogs [TUSOM | Pharmwiki]](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-025-90896-2/MediaObjects/41598_2025_90896_Fig6_HTML.png)
![basal insulin and glp-1 Adding a receptor agonist was not associated with a lower likelihood of discontinuing existing therapy among veterans with type 2 diabetes compared with other glucose-lowering agents, a target emulation glp-1_analogs [TUSOM | Pharmwiki]](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs13098-025-01623-w/MediaObjects/13098_2025_1623_Figa_HTML.png)
![basal insulin and glp-1 Adding a receptor agonist was not associated with a lower likelihood of discontinuing existing therapy among veterans with type 2 diabetes compared with other glucose-lowering agents, a target emulation glp-1_analogs [TUSOM | Pharmwiki]](https://revolutionhealth.org/cdn/shop/articles/What_is_GLP-1_9e9d1b41-2be6-410c-bc3a-855652d1bef7.png?v=1768865020&width=1100)
![basal insulin and glp-1 Adding a receptor agonist was not associated with a lower likelihood of discontinuing existing therapy among veterans with type 2 diabetes compared with other glucose-lowering agents, a target emulation glp-1_analogs [TUSOM | Pharmwiki]](https://framerusercontent.com/images/1uCO0aYx4x9CoG1BwhPl3RqIOfM.png)
